NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2026)
NewAmsterdam Pharma's (NAMS) quarterly EBITDA Margin came in at 1612.27% in Q1 2026, down 28386.0% year-on-year from N/an in Q1 2025, and up 99.31% quarter-over-quarter from 233656.25% in Q4 2025.
NewAmsterdam Pharma (NAMS) EBITDA Margin (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has disclosed EBITDA Margin across 4 years of filings, most recently posting 1612.27% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 1612.27%, down 28386.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 943.7% (down 54628.0% YoY), and the FY2025 annual result was 904.29%, down 37414.0% from the prior year.
- EBITDA Margin came in at 1612.27% for Q1 2026 at NewAmsterdam Pharma, up from 233656.25% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 57.18% in Q3 2024 to a low of 233656.25% in Q4 2025.
- The 4-year median for EBITDA Margin is 1612.27% (2026), against an average of 21304.29%.
- Across the five-year window, EBITDA Margin soared 544240 bps in 2024 and tumbled 23293489 bps in 2025, its largest moves.
- NewAmsterdam Pharma's EBITDA Margin stood at 6163.76% in 2023, then jumped by 88 bps to 721.36% in 2024, then tumbled by 32291 bps to 233656.25% in 2025, then surged by 99 bps to 1612.27% in 2026.
- The last three EBITDA Margin figures came in at 1612.27% (Q1 2026), 233656.25% (Q4 2025), and 20601.15% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - | -1,612.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,612.27% |
| Dec 31, 2025 | -233,656.25% |
| Sep 30, 2025 | -20,601.15% |
| Jun 30, 2025 | -91.26% |
| Mar 31, 2025 | -1,328.41% |
| Dec 31, 2024 | -721.36% |
| Sep 30, 2024 | -57.18% |
| Jun 30, 2024 | -1,711.58% |
| Mar 31, 2024 | -6,692.86% |
| Dec 31, 2023 | -6,163.76% |
| Sep 30, 2023 | -1,602.62% |
| Jun 30, 2023 | -2,230.11% |
| Mar 31, 2023 | -486.94% |